



ASX ANNOUNCEMENT

22 November 2013

CONDITIONAL REINSTATEMENT APPROVAL

The Board of Cynata Therapeutics Limited (ASX: CYP) is pleased to advise that the ASX has provided conditional approval for the reinstatement of the Company's securities to official quotation following completion of its change in activities.

The approval is subject to a range of conditions which are acceptable to the Board and which the Company is in the process of responding to.

Consistent with the announcement made on 26 September 2013, the Board expects the Company's securities to commence trading later this month, subject to ASX approval.

Dr Ross Macdonald

Managing Director & Chief Executive Officer

About Cynata Therapeutics Limited

Cynata Therapeutics Ltd is an Australian stem cell and regenerative medicine company that is developing a therapeutic stem cell platform technology, Cymerus™, originating from the University of Wisconsin-Madison, a world leader in stem cell research. The proprietary Cymerus™ technology seeks to address a critical shortcoming in existing methods of production of mesenchymal stem cells (MSCs) for therapeutic use, which is the ability to achieve economic manufacture at commercial scale. Cymerus™ does so through the production of a particular type of MSC precursor, called a mesenchymoangioblast (MCA). The Cymerus™ MCA platform provides a source of MSCs that is independent of donor limitations and provides a potential "off-the-shelf" stem cell platform for therapeutic product use, with a pharmaceutical business model and economies of scale. This has the potential to create a new standard in the emergent arena of stem cell therapeutics and provides both a unique differentiator and an important competitive position.